Trial Profile

Multicenter, Randomized, Double Blind, Placebo-Controlled Phase 2a Study, to Evaluate Safety, Tolerability and Pharmacokinetics of Resveratrol (JOTROLTM) in Parkinson's Disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 May 2026 According to Jupiter Neurosciences media release, patient enrollment is underway in the trial.
27 May 2026 Status changed from not yet recruiting to recruiting.
21 May 2026 According to Jupiter Neurosciences media release, announced the closing of a registered direct offering that generated gross proceeds of approximately US$2.0 million through the sale of 7,142,858 shares of common stock. The proceeds will provide funding for the company's Parkinson's disease development program and enable execution of the planned phase IIa clinical trial in patients with Parkinson's disease.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com